New York — Healthcare investment firm OrbiMed has raised its total investment in Swiss dental company vVARDIS to $85 million, the two companies announced recently. vVARDIS is known for its drill-free treatment for early tooth decay.
OrbiMed closed a $50 million funding round, adding to an earlier $35 million investment made in February 2025.
Matthew Rizzo, general partner at OrbiMed, said, “After our initial investment, we’ve seen the strong momentum vVARDIS is building in the dental market with its Curodont™ products.” He added that Curodont is “gaining real traction.”
Treatment Available in Nearly 10% of U.S. Dental Offices
Drs. Haley and Goly Abivardi, founders and co-CEOs of vVARDIS, said Curodont is now available in about 10 percent of dental offices across the United States.
Since January 2024, more than one million teeth have been treated with Curodont in the U.S. Over 400,000 patients have received treatment so far this year, according to the company’s statement.
“That’s why we are excited to deepen our commitment and expand our investment to support vVARDIS as it enters its next phase of growth,” Rizzo said.
FDA-Approved Since 2019
Curodont received CE marking for use in the European Union and Switzerland in 2012. It entered various international markets starting in 2016. The treatment received clearance from the U.S. Food and Drug Administration (FDA) in 2019, allowing it to be sold in the United States.
Young Innovations, a dental supplies manufacturer and distributor based in Algonquin, Illinois, began distributing Curodont Repair Fluoride Plus in 2021.
In September 2024, Henry Schein became the exclusive U.S. distributor for Curodont Repair Fluoride Plus. This treatment offers a non-invasive preventive option for early-stage cavities.